# OKYO catalysts: OKYO Pharma Ltd PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/okyo/catalysts

> OKYO Pharma Ltd (OKYO) has 2 upcoming catalysts. The next is the urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered qid for 12-weeks. primary completion, May 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | OKYO Pharma Ltd |
| Ticker | OKYO (Nasdaq) |
| SEC CIK | 1849296 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/okyo |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 6, 2023 | [Urcosimod trial start](https://sec-api.dev/pdufa/urcosimod) | OKYO |  | completed | "June 6, 2023, we announced that patients in the ongoing phase 2b trial began dosing in the randomized portion of the phase 2b, multi-center, double-masked, placebo-controlled trial of topical ocular urcosimod to treat DED, following the two-week placebo run-in period intended to minimize the placebo effect." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm)) |
| Jan 2024 | [Urcosimod topline data readout](https://sec-api.dev/pdufa/urcosimod) | OKYO | DED patients | completed, positive | "January of 2024, OKYO reported positive top line data from the Phase 2b trial of OK-101 to treat DED patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1849296/000149315225004156/ex99-1.htm)) |
| Q4 2025 | [Neuropathic topline data readout](https://sec-api.dev/pdufa/neuropathic) | OKYO |  | scheduled | "The company is planning to release top-line results in Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1849296/000149315225006035/ex99-1.htm)) |
| Q4 2025 | [Urcosimod topline data readout](https://sec-api.dev/pdufa/urcosimod) | OKYO |  | scheduled | "Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1849296/000149315225004156/ex99-1.htm)) |
| 2026 | [Urcosimod topline data readout](https://sec-api.dev/pdufa/urcosimod) | OKYO |  | scheduled | "We anticipate topline results from this trial in 2026, with ongoing negotiations for clinical sites." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1849296/000149315226004550/ex99-2.htm)) |
| January 23, 2026 | [Urcosimod FDA approval](https://sec-api.dev/pdufa/urcosimod) | OKYO |  | completed, approved | "January 23, 2026, we announced that the FDA approved compassionate use of urcosimod (0.05%) for treatment of neuropathic corneal pain." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1849296/000149315226006946/form424b5.htm)) |
| 2H 2026 | [Urcosimod trial start](https://sec-api.dev/pdufa/urcosimod) | OKYO |  | scheduled | "OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1849296/000149315226044760/ex99-1.htm)) |
| May 2027 | [Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered qid for 12-weeks. primary completion](https://sec-api.dev/pdufa/urcosimod-ophthalmic-solution-is-a-preservative-free-topical-ophthalmic-product-) | OKYO | Neuropathic Corneal Pain | scheduled | "NCT07838506 (Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Okyo Pharma Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07838506)) |
| May to Aug 2027 | [Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered qid for 12-weeks. topline data readout](https://sec-api.dev/pdufa/urcosimod-ophthalmic-solution-is-a-preservative-free-topical-ophthalmic-product-) | OKYO | Neuropathic Corneal Pain | scheduled | "NCT07838506 (Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Okyo Pharma Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07838506)) |

## Drugs

- [Neuropathic](https://sec-api.dev/pdufa/neuropathic): 
- [Urcosimod](https://sec-api.dev/pdufa/urcosimod): ded patients
- [Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered qid for 12-weeks.](https://sec-api.dev/pdufa/urcosimod-ophthalmic-solution-is-a-preservative-free-topical-ophthalmic-product-): Neuropathic Corneal Pain

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/okyo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OKYO catalysts: OKYO Pharma Ltd PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/okyo/catalysts

```bibtex
@misc{secapidev_companies_okyo_catalysts_20261116,
  title        = {OKYO catalysts: OKYO Pharma Ltd PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/okyo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_okyo_catalysts_20261116","title":"OKYO catalysts: OKYO Pharma Ltd PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/okyo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
